Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vireo GrowthVREOF +0.08%51 Cash-to-Debt is 0.21 as of Jun. 2026, which is 56% below its 10-year median of 0.48. GuruFocus rates VREOF with a GF Score™ of 51/100 and a GF Value™ of $11.93 (Fairly Valued). The stock has 6 warning signs investors should review. Among 983 Drug Manufacturers companies, Vireo Growth ranks worse than 76.3% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vireo Growth's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.21.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Vireo Growthcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Vireo Growth's Cash-to-Debt or its related term are showing as below:
VREOF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.48 Max: No Debt
Current: 0.21
During the past 13 years, Vireo Growth's highest Cash to Debt Ratio was No Debt. The lowest was 0.08. And the median was 0.48.
VREOF's Cash-to-Debt is ranked worse than 76.3% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs VREOF: 0.21
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Vireo Growth Cash-to-Debt Related Terms
Vireo Growth Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (VREOF) has a Cash-to-Debt of 0.21 as of Jun. 2026. This is 56% below median its historical median of 0.48. Over the past decade, Vireo Growth's Cash-to-Debt has ranged from 0.08 to 10,000.00. According to the industry distribution chart, Vireo Growth ranks #750 out of 983 companies in the Drug Manufacturers industry, placing it in the top 76.3%.
Is Vireo Growth's Cash-to-Debt too high?
Vireo Growth's current Cash-to-Debt of 0.21 is 56% below median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.96. Vireo Growth's value of 0.21 is 78.1% below this industry median. Based on the distribution chart, Vireo Growth ranks #750 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vireo Growth has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #750 out of 983 companies for Cash-to-Debt. This places Vireo Growth in the lower half of its industry. The industry median Cash-to-Debt is 0.96. Vireo Growth's value of 0.21 is 78.1% below this benchmark. Historically, Vireo Growth's own Cash-to-Debt has ranged from 0.08 to 10,000.00 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 0.96, Vireo Growth has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current Cash-to-Debt of 0.21 is 78.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Cash-to-Debt is 0.21, which is 56% below median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Fairly Valued. The stock's GF Value™ is $11.93, compared to a current price of $12.00 — trading 0.6% above its estimated fair value. The current Cash-to-Debt is 0.21, which is 56% below median its 10-year median of 0.48 and 78.1% below the Drug Manufacturers industry median of 0.96. Vireo Growth's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Vireo Growth (VREOF), the current Cash-to-Debt is 0.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of $12.00 is trading 0.6% above its estimated GF Value™ of $11.93.
GuruFocus considers Vireo Growth to be Fairly Valued.
Key valuation signals for VREOF:
Cash-to-Debt: 0.21 (56% below median its 10-year median of 0.48)
GF Value™: $11.93 vs. price of $12.00 (0.6% above fair value)
Industry Position: 78.1% below the Drug Manufacturers median (#750 of 983)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
51GF Score
Get the complete analysis for VREOF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 
